Stockscreener 앱 받기
0.93%
전일 마감가:
$25.89
열려 있는:
$25.89
하루 거래량:
59.20M
Relative Volume:
0.95
시가총액:
$145.84B
수익:
$62.79B
순이익/손실:
$9.84B
주가수익비율:
14.95
EPS:
1.7156
순현금흐름:
$10.38B
1주 성능:
+0.67%
1개월 성능:
+0.47%
6개월 성능:
+4.23%
1년 성능:
-3.17%
1일 변동 폭
$25.55
$25.89
1주일 범위
$24.97
$25.89
52주 변동 폭
$20.91
$27.69
화이자 Stock (PFE) Company Profile
명칭
Pfizer Inc
전화
(212) 733-2323
주소
66 HUDSON BOULEVARD EAST, NEW YORK, NY
PFE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.65 | 147.20B | 62.79B | 9.84B | 10.38B | 1.7156 |
|
LLY
Lilly Eli Co
|
1,038.40 | 924.53B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
218.66 | 529.01B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
214.35 | 383.08B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVO
Novo Nordisk Adr
|
62.33 | 253.81B | 46.69B | 15.29B | 9.25B | 3.4329 |
|
NVS
Novartis Ag Adr
|
144.34 | 274.68B | 54.45B | 14.42B | 17.15B | 7.333 |
화이자 Stock (PFE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-02 | 재개 | Citigroup | Neutral |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-25 | 재개 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | 다운그레이드 | Argus | Buy → Hold |
| 2024-02-23 | 개시 | Guggenheim | Buy |
| 2024-01-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-10-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-17 | 재확인 | JP Morgan | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-06-29 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-01-17 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-12-13 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-20 | 재확인 | Cowen | Outperform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-13 | 업그레이드 | UBS | Neutral → Buy |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-12-16 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 재개 | Goldman | Neutral |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-10-12 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-16 | 개시 | SVB Leerink | Mkt Perform |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-27 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-07-30 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 재개 | Morgan Stanley | Overweight |
| 2019-02-20 | 재개 | Citigroup | Neutral |
| 2019-01-31 | 업그레이드 | Argus | Hold → Buy |
| 2019-01-31 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | 다운그레이드 | UBS | Buy → Neutral |
| 2018-12-11 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-11-01 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
모두보기
화이자 주식(PFE)의 최신 뉴스
Pfizer stock slips into MLK Day break as FDA fast-track fears and key dates loom - TechStock²
Pfizer Inc Is On Sale: Viral Hype Or Big Pharma Value Trap? - AD HOC NEWS
Key facts: Pfizer's stock yields 6.7%; CEO criticizes vaccine plan - TradingView — Track All Markets
Pfizer stock slips into holiday week as CEO filing, vaccine-policy row and biotech IPO news land - TechStock²
Could Pfizer Inc.'s (NYSE:PFE) Weak Financials Mean That The Market Could Correct Its Share Price? - Yahoo Finance
Key facts: Pfizer's stock yields 6.7%; explores FDA program; Chantix study results - TradingView — Track All Markets
Lobbying Update: $60,000 of PFIZER INC. lobbying was just disclosed - Quiver Quantitative
Pfizer: Rebound Has Just Started (NYSE:PFE) - Seeking Alpha
Pfizer (PFE) CEO Isn't Ready For A Fight With RFK Jr., Says Jim Cramer - Finviz
Pfizer (PFE) CEO Isn’t Ready For A Fight With RFK Jr., Says Jim Cramer - Yahoo Finance
GWN Securities Inc. Lowers Stake in Pfizer Inc. $PFE - MarketBeat
Actionable Insights in the Dermatology Market: Navigating Technological Advances and Growth Trends - GlobeNewswire Inc.
Pfizer Stock Just Flipped the Script: Crash, Comeback, or Total Cap? - AD HOC NEWS
Pfizer’s Abrocitinib Atopic Dermatitis Study Nears Data Milestone: What Investors Should Watch - TipRanks
Campbell & CO Investment Adviser LLC Has $3.38 Million Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Has The Market Overlooked Pfizer (PFE) After The Post‑Pandemic Reset? - simplywall.st
Atopic Dermatitis Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regeneron Pharma, Abbvie, Allergan - Barchart.com
Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook - TechStock²
Why Pfizer Inc. (PFE) is One of the Best Affordable Stocks Under $30 - Finviz
Pfizer Advances Prazosin Manufacturing Shift With New Bioequivalence Study - TipRanks
Pfizer’s TOFAst Real-World Study in Ulcerative Colitis: What Investors Should Watch - TipRanks
News | Expect more big loan pools in 2026; Loan refinances San Diego Pfizer campus; Critical refinancing tests loom - CoStar
Pfizer Stock Under Pressure: Is This Pharma Giant a Deep Value Play or a Value Trap? - AD HOC NEWS
Pfizer: The Most Intriguing Value Play Of 2026 (NYSE:PFE) - Seeking Alpha
Pfizer’s Strategic Pivot: Obesity Drug Push and Regulatory Tailwinds - AD HOC NEWS
Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer (NYSE:PFE) Trading 1.6% HigherWhat's Next? - MarketBeat
Pfizer (PFE) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
Pfizer Inc - Reuters
Pfizer (PFE) stock rises as CEO calls obesity push a “Viagra”-scale bet, with earnings next in focus - TechStock²
Pfizer stock rises as CEO likens obesity-drug boom to Viagra ahead of Feb. 3 earnings - TechStock²
Pfizer Completes Key China Phase 3 Trial for Migraine Drug Rimegepant - TipRanks
Pfizer’s Strategic Pivot Meets Skeptical Market Response - AD HOC NEWS
Novo’s CEO Is Ready to Go ‘Very Big’ in Hunt for Obesity Deals - Bloomberg.com
Bull Run: Why Pfizer Inc stock remains on watchlistsOil Prices & Risk Managed Investment Entry Signals - moha.gov.vn
Should Pfizer’s Oncology Win And Obesity Push Require Action From Pfizer (PFE) Investors? - simplywall.st
JPM26: Pfizer’s Metsera deal supercharges its obesity strategy - Yahoo Finance
Pfizer CEO Says Company Is Pushing for FDA Priority Review Voucher - Yahoo Finance
Pfizer Ends Mid-Stage Lupus Skin Trial, Trimming a Small but Promising Autoimmune Option - TipRanks
Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra” - TechStock²
Inside Pfizer's Oncology Performance Ahead of Q4 Results - The Globe and Mail
JPM26: Pfizer Fast-Tracks Obesity Programs in Race Against Patent Cliff - BioSpace
TD Private Client Wealth LLC Acquires 80,571 Shares of Pfizer Inc. $PFE - MarketBeat
Tema Etfs LLC Purchases Shares of 93,166 Pfizer Inc. $PFE - MarketBeat
Antidepressant Market Is Booming So Rapidly | Eli Lilly and Company, Pfizer Inc., GlaxoSmithKline PLC, AstraZeneca - openPR.com
Pfizer's Patent Cliff, Rising Debt, And The Fight To Stay A Buy (NYSE:PFE) - Seeking Alpha
Pfizer Inc. (NYSE:PFE) is favoured by institutional owners who hold 66% of the company - Yahoo Finance
Bogart Wealth LLC Raises Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer CEO Eyes Big Push Towards Obesity Drug Development In 2026 After $10B Metsera Acquisition - Stocktwits
Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare ConferenceSlideshow (NYSE:PFE) 2026-01-13 - Seeking Alpha
(01/13/26) Top Picks 2026: Pfizer Inc. (PFE) - moneyshow.com
화이자 (PFE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.01%
1.85%
자본화:
|
볼륨(24시간):